Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers
Medinno has raised more than RMB 200 million in a Series A financing led by Sunshine Ronghui Capital, giving the company fresh funding to develop MDI-1228, a topical drug candidate for diabetic foot ulcers and other conditions. The proceeds will support…
GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million
GSK is expanding its relationship with China’s Chimagen Biosciences, agreeing to acquire global rights to an experimental trispecific T-cell engager for multiple myeloma in a transaction worth up to $750 million. The agreement, announced September 15,…
Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial
Forlong Biotech has completed the second close of its Pre-B financing, bringing the round’s total to nearly RMB 200 million. Fosun Health Capital’s new drug fund led the latest close, which raised more than RMB 100 million, according to Chinese financing…
ApicHope’s AR882 Beats Febuxostat in China Phase 3 Gout Trial, Meeting Primary Endpoint
China’s ApicHope Pharmaceutical Group has reported positive topline results from a Phase 3 clinical trial of AR882 (pozdeutinurad), its next-generation URAT1 inhibitor for gout, showing statistically significant superiority over febuxostat in lowering…
Biokin Pharmaceutical
Building a Global Oncology Franchise Around Bispecific ADCs
Haisco Pharmaceutical Group
From Chinese Specialty Pharma to Global Innovative Drug Developer
Akeso, Inc.
Building a Global Bispecific Antibody and Next-Generation Oncology Franchise
Leads Biolabs’ Opamtistomig NDA Accepted in China, Setting Up Potential World-First 4-1BB Therapy
Nanjing Leads Biolabs announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for Opamtistomig (LBL-024), the company’s internally developed…
DAJO Bio Raises Tens of Millions of RMB in Seed Financing to Advance Next-Generation TCR Protein Therapies
Shenzhen-based biotechnology startup DAJO Bio (“DAJO”) has completed a seed financing round worth tens of millions of RMB, providing fresh capital to advance its next-generation T-cell receptor (TCR) protein therapeutic platforms and pipeline…
Keymed completed Phase 2 trial of CM512, a TSLP x IL-13 bispecific antibody for chronic sinusitis
The Phase II clinical trial of long-acting TSLP x IL-13 bispecific antibody CM512 for the treatment of chronic sinusitis with nasal polyps (CRSwNP) has met all study endpoints.